Form 4: Outset Medical SVP Marc Nash Granted Over 29,000 Restricted Stock Units

Outset Medical, Inc. SVP of Operations and R&D, Marc Nash, was granted 29,676 restricted stock units (RSUs) on June 10, 2025, as part of his compensation.

Summary

• Marc Nash, the Senior Vice President of Operations and R&D at Outset Medical, Inc. (OM), received a grant of 29,676 Restricted Stock Units (RSUs) on June 10, 2025.
• Each RSU represents a contingent right to receive one share of Outset Medical common stock.
• The RSUs are subject to a vesting schedule: 50% will vest on January 17, 2026.
• The remaining 50% will vest in equal quarterly installments on February 15th, May 15th, August 15th, and November 15th of the following year (2027).
• Vesting is contingent upon Mr. Nash's continuous service to the company through the applicable vesting dates.
• Following this transaction, Marc Nash's beneficial ownership of Outset Medical common stock totals 43,141 shares.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key executive is generally a positive signal for retention and alignment of interests, though it's a routine compensation event rather than a major strategic announcement that would significantly alter the company's outlook.

Positives

• The grant of 29,676 Restricted Stock Units (RSUs) to a key executive like Marc Nash helps align management incentives with long-term shareholder interests.
• This RSU grant indicates the company's commitment to retaining and compensating a senior leader in a critical role (SVP Operations and R&D).

Risks

• The vesting of the granted Restricted Stock Units (RSUs) is contingent upon Marc Nash's continuous service to Outset Medical, meaning the shares could be forfeited if his employment ceases before the specified vesting dates.

Future Outlook

This SEC Form 4 filing details an executive's equity compensation grant and does not provide any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider equity transaction. It reflects a common practice in the medical device industry, and publicly traded companies generally, to use equity-based compensation like Restricted Stock Units to attract, retain, and incentivize key executives by aligning their financial interests with the long-term performance of the company.

Related Party Transactions

• The grant of Restricted Stock Units to Marc Nash, a Senior Vice President of Outset Medical, Inc., constitutes a related party transaction as it involves compensation between the company and an executive officer.

Stakeholder Impact

• Shareholders: The RSU grant, upon vesting, will result in a minor dilution of existing shares but aims to align the executive's interests with long-term shareholder value creation.
• Employees: This specific grant is for a senior executive and does not directly impact the broader employee base, though it reflects the company's overall executive compensation strategy.

Next Steps

• Marc Nash's continued service to Outset Medical, Inc. is required for the vesting of the granted RSUs.
• Future SEC Form 4 filings will report any subsequent changes in Marc Nash's beneficial ownership of Outset Medical securities.

Key Dates

Recommendation

Keywords

Outset Medical, OM, Marc Nash, Restricted Stock Units, RSU, Stock Grant, Executive Compensation, Insider Transaction, SEC Form 4, Beneficial Ownership, Medical Devices